Home > Insider Trading > Filing (0001127602-17-019588)

Filing Details

Accession Number:: 0001127602-17-019588
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-05-26 19:20:50
Reporting Period:: 2017-05-24

Filing Date:: 2017-05-26
Accepted Time:: 2017-05-26 19:20:50
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1681689	Bioverativ Inc.	BIVV	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1361754	J Alexander Denner	C/O Bioverativ Inc. 225 Second Avenue Waltham MA 02451		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-05-24	340,000	$54.16	495,000	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2017-05-25	130,000	$54.98	625,000	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2017-05-26	450,000	$57.21	1,075,000	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	5,001	Direct

Footnotes

On May 24, 2017, each of Sarissa Capital Domestic Fund LP, a Delaware limited partnership ("Sarissa Domestic") and Sarissa Capital Offshore Master Fund LP, a Cayman Islands exempt limited partnership ("Sarissa Offshore" and together with Sarissa Domestic, the "Sarissa Funds"), purchased an aggregate of 295,800 and 44,200 shares, respectively, of common stock of Bioverativ Inc.
On May 25, 2017, each of Sarissa Domestic and Sarissa Offshore purchased an aggregate of 113,100 and 16,900 shares, respectively, of common stock of Bioverativ Inc.
On May 26, 2017, each of Sarissa Domestic and Sarissa Offshore purchased an aggregate of 391,500 and 58,500 shares, respectively, of common stock of Bioverativ Inc.
Full information regarding the number of shares purchased at each separate price will be provided upon request by the SEC staff, the issuer or a security holder of the issuer.
This represents the weighted average price for shares purchased at a range between $54.0278 (low) and $54.2631 (high).
This represents the weighted average price for shares purchased at a range between $54.9826 (low) and $54.9994 (high).
This represents the weighted average price for shares purchased at a range between $57.1471 (low) and $57.5297 (high).
Includes (i) 390,871 shares beneficially owned by Sarissa Domestic and (ii) 104,129 shares beneficially owned by Sarissa Offshore.
Includes (i) 503,971 shares beneficially owned by Sarissa Domestic and (ii) 121,029 shares beneficially owned by Sarissa Offshore.
Includes (i) 895,471 shares beneficially owned by Sarissa Domestic and (ii) 179,529 shares beneficially owned by Sarissa Offshore.
Alexander Denner, Ph.D. is the Chief Investment Officer of Sarissa Capital Management LP, a Delaware limited partnership ("Sarissa Capital"), the investment advisor to the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.